Results 81 to 90 of about 52,753 (266)

Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems

Journal of Nanobiotechnology, 2018
Background Recent work has developed solid drug nanoparticles (SDNs) of efavirenz that have been demonstrated, preclinically, improved oral bioavailability and the potential to enable up to a 50% dose reduction, and is currently being studied in a ...
Neill J. Liptrott, Marco Giardiello, Tom O. McDonald, Steve P. Rannard, Andrew Owen   +4 more
doaj   +1 more source

A sensitive and selective liquid chromatography/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma. [PDF]

PLoS ONE, 2013
A selective and a highly sensitive method for the determination of the non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz, in human plasma has been developed and fully validated based on high performance liquid chromatography tandem mass ...
Praveen Srivastava, Ganesh S Moorthy, Robert Gross, Jeffrey S Barrett   +3 more
doaj   +1 more source

Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential

Annals of Internal Medicine, 2019
Dolutegravir-based antiretroviral therapy (ART) for persons with HIV offers superior efficacy and tolerability compared with efavirenz-based ART, which has long been recommended by the World Health Organization (WHO) as the preferred first-line regimen ...
C. Dugdale, A. Ciaranello, L. Bekker, Madeline Stern, L. Myer, R. Wood, P. Sax, E. Abrams, K. Freedberg, R. Walensky   +9 more
semanticscholar   +1 more source

HUBUNGAN ANTARA PEMAKAIAN EFAVIRENZ DENGAN EFEK SAMPING NEUROPSIKIATRI PADA PASIEN HIV/AIDS : Studi Kasus di RSUP dr. Kariadi Semarang [PDF]

, 2015
Background: HIV/AIDS has been a global problem. Antiretroviral therapy is currently an effective therapy for HIV/AIDS. Efavirenz is an antiretroviral agent which commonly cause neuropsychiatric adverse events.
Ngestiningsih, Dwi, Salsabillah, Farah, Sofro, Muchlis Achsan Udji   +2 more
core  

Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. [PDF]

, 2010
INTRODUCTIO
Baroncelli, Bera, Boulle, Bussmann, Chersich, Correa, De Clercq, De Santis, Fernandez Ibieta, Fleiss, Floridia, Fundaro, Goujard, Guyatt, Jeantils, Joao, Machado, Meade, Nachega, Patel, Rankin, Rossouw, Saitoh, Sheehe, Shepard, Townsend, Venter, Watts   +27 more
core   +3 more sources

Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine

Pharmacogenetics & Genomics, 2020
Supplemental Digital Content is available in the text. Objectives The effect of rifapentine plus isoniazid on efavirenz pharmacokinetics was characterized in AIDS Clinical Trials Group protocol A5279 (NCT01404312).
D. Haas, A. Podany, Yajing Bao, S. Swindells, R. Chaisson, N. Mwelase, K. Supparatpinyo, L. Mohapi, Amita Gupta, C. Benson, Paxton Baker, C. Fletcher   +11 more
semanticscholar   +1 more source

Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe

BMC Infectious Diseases, 2019
Background Gynecomastia is known to occur in some men taking an efavirenz-based antiretroviral therapy (ART) regimen. However, the incidence and outcomes of gynecomastia are not known in Zimbabwe.
Sandra Shawarira-Bote, Tinei Shamu, Cleophas Chimbetete   +2 more
doaj   +1 more source

Hubungan Antara Pemakaian Efavirenz Dengan Efek Samping Neuropsikiatri Pada Pasien Hiv/aids [PDF]

, 2015
Background: HIV/AIDS has been a global problem. Antiretroviral therapy is currently an effective therapy for HIV/AIDS. Efavirenz is an antiretroviral agent which commonly cause neuropsychiatric adverse events.Aim: To investigate the association between ...
Chasani, S. (Shofa), Ngestiningsih, D. (Dwi), Salsabila, F. (Farah), Sofro, M. A. (Muchlis)   +3 more
core  

In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds

Journal of Medicinal Chemistry, 2019
Cytochrome P450 46A1 (CYP46A1) is a central nervous system-specific enzyme, which catalyzes cholesterol 24-hydroxylation. Currently CYP46A1 is being evaluated in a clinical trial for activation by small doses of the anti-HIV drug efavirenz.
Natalia Mast, P. Verwilst, Clayton J. Wilkey, F. Guengerich, I. Pikuleva   +4 more
semanticscholar   +1 more source

The Creation of a Weight of Evidence Scoring Database for Risk Factors for Adverse Impacts to Birth Outcomes Using Expert Elicitation

Birth Defects Research, Volume 118, Issue 1, January 2026.
ABSTRACT Background Adverse birth outcomes are important public health measures and account for a substantial public health burden. There is considerable diversity of these health endpoints, as well as in the many factors suspected or recognized to increase their risk.
Paul J. Villeneuve, Ann Aschengrau, Michelle L. Bell, Yang Cao, Mark Elwood, Guy Eslick, Shelley Harris, Leeka Kheifets, Babak Khoshnood, Robert Norman, Nelson Pace, Johan Reutfors, Jeremy M. Schraw, Jose R. Suarez‐Lopez, Gunnar Toft, R. Douglas Wilson, Christopher R. Kirman, Tyler Carneal, Sean M. Hays   +18 more
wiley   +1 more source